Independent. No tobacco money. No corporate fluff.MON, AUG 24

PouchDaily

The daily pulse of the nicotine pouch market

Regulation
US

FDA greenlights 11 ZYN Ultra pouches — including its first 11mg

On 21 August 2026 the FDA issued Marketing Granted Orders for 11 ZYN Ultra nicotine pouches from Swedish Match USA — ten 9mg flavours and a new 11mg Smooth. The authorizations push the total of FDA-authorized nicotine pouch products to 43, with 23 cleared through the agency’s nicotine pouch pilot program. The American Lung Association attacked the move, citing youth appeal.

PouchDaily Desk·
ZYNZYN UltraFDAPMTAMarketing Granted OrderPhilip Morris InternationalSwedish Matchnicotine pouchregulationyouth useAmerican Lung Associationpublic health

The US Food and Drug Administration has authorized 11 ZYN Ultra nicotine pouch products from Swedish Match USA, including a new 11mg pouch — the highest nicotine strength the agency has cleared for any pouch to date.

The Marketing Granted Orders (MGOs), issued on 21 August 2026 through the FDA's Premarket Tobacco Product Application (PMTA) pathway, cover ten 9mg flavours — Chill, Citrus, Cool Mint, Deep Freeze, Menthol, Peppermint, Smooth, Spearmint, Wintergreen Chill and Wintergreen — plus ZYN Ultra Smooth at 11mg. Philip Morris International said additional 11mg variants remain under scientific review.

The decision brings the total number of FDA-authorized nicotine pouch products to 43, with 23 cleared through the agency's nicotine pouch pilot program, according to Tobacco Reporter and the FDA.

What happened

This is a PMTA marketing authorization — not the same thing as a safety approval. A Marketing Granted Order means the FDA has determined that allowing a product to be marketed is "appropriate for the protection of public health," the statutory standard for new tobacco products. It does not mean the pouches are safe or "FDA approved," the agency and Nicotine Insider both stressed.

The FDA said its scientific review found the ZYN Ultra products contain lower levels of most harmful and potentially harmful constituents than other oral and smokeless tobacco products, with many present at levels too low to quantify. Swedish Match provided product-specific data showing the pouches appeal primarily to adults who currently smoke cigarettes or use smokeless tobacco and could provide enough nicotine to reduce cravings and withdrawal symptoms, potentially supporting switching.

The 11mg authorization is the part that breaks new ground. Manufacturers have been pushing into higher-strength pouches, and the FDA noted that it evaluated the 11mg version individually — considering product design, formulation and materials that affect how much nicotine reaches a user and how quickly, not just the labelled milligram number.

"For adults 21 and older who use smokeless tobacco or smoke cigarettes, switching completely to FDA-authorized nicotine pouches may reduce exposure to many harmful chemicals found in smokeless tobacco or cigarettes," the FDA said, calling the authorizations "another important step to provide greater access to potentially less harmful alternative tobacco products for existing adult tobacco users."

Stacey Kennedy, PMI US CEO, said: "We are delighted with the FDA's decision to authorize a range of ZYN ULTRA products, which will build on ZYN's position as America's leading smoke-free product brand. We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products."

Why it matters

The authorization matters on three fronts.

First, the pilot program is accelerating. The FDA created the nicotine pouch pilot specifically to speed and streamline PMTA reviews. The agency said it has led to faster issue resolution, shorter applicant response times to deficiency letters and more efficient scientific reviews — and that it is already applying those efficiencies to other pending PMTAs. That means the ZYN Ultra decisions could signal a faster authorization pipeline for the entire category, not just one brand.

Second, the 11mg ceiling is moving. Until now the FDA's authorized ZYN lineup topped out at 6mg (with the flagship line) and the higher-strength Ultra range pending. Clearing an 11mg pouch sets a new regulatory benchmark for strength — one competitors designing high-strength formats will now measure themselves against. The FDA was careful to frame the decision as product-specific rather than a blanket green light for high nicotine, but the precedent is set.

Third, the public-health fight is intensifying. The authorization landed less than two months after the FDA issued Modified Risk Tobacco Product (MRTP) orders for 20 ZYN products on 30 June 2026 — the first time any pouch brand was cleared to advertise a reduced-disease-risk claim versus cigarettes. We covered that decision and the medical pushback in detail: FDA lets ZYN claim it's safer than cigarettes — doctors push back. The PMTA and MRTP pathways are separate, but together they mark the fastest regulatory expansion the US pouch category has seen.

The American Lung Association pushes back

Thomas Carr, Director of National Policy at the American Lung Association, sharply criticized the decision.

"Once again, FDA is rolling the dice with the health of kids and young adults by authorizing 11 new flavored nicotine pouches, all with high levels of nicotine," Carr said. "Of kids who use nicotine pouches, 70% reported using Zyn as their brand, and 60.9% use mint, making it the most popular flavor with kids."

Carr also questioned whether the pilot program's emphasis on speed compromises scrutiny: "FDA's continued authorization of nicotine pouches through a pilot program designed to speed up the review process raises serious questions about whether these products are receiving the rigorous scientific scrutiny necessary to protect public health."

The youth-use concern is not abstract. The most recent National Youth Tobacco Survey found roughly 460,000 middle and high school students reported using nicotine pouches in the past year, making pouches the second most commonly used tobacco product among young Americans behind e-cigarettes. Several of the flavors just authorized — Cool Mint, Menthol, Peppermint, Wintergreen — sit in the mint family that the ALA says dominates youth use.

What's next

The remaining 11mg ZYN Ultra variants are still under FDA scientific review, so the high-strength lineup could expand further. More broadly, the pilot program's efficiencies are being applied to other pending PMTAs, which means competing brands with applications in the queue may see faster decisions — raising the stakes for the youth-appeal debate the ALA has now put squarely on the table.

The FDA continues to state that "there is no safe tobacco product" and that non-users should not start. A Marketing Granted Order is a market-access decision, not an endorsement — the distinction the agency, PMI and public health groups will keep arguing over as the authorized pouch count climbs.

ZYN Ultra launched in the US in June 2026 as a moist, slim, 20-pouch-per-can format built to defend ZYN's share against Velo Plus, FRE and ALP. We broke down the product specs and competitive logic here: ZYN Ultra: PMI goes moist and high-strength to hold off Velo and On!.

Compare ZYN prices across retailers at PouchFinder.

SOURCES: